Pharmaceutical Industry Articles & Reports - Page 2

Build a reproducible FDA DECRS supplier verification pipeline in 2026: daily snapshots, current vs excluded files, a tiered match rubric, 65-day expiry arithmetic and a human review queue.

Data report on Claude AI pharma R&D automation: Anthropic's Sept 17, 2026 AL0-AL5 index (26% leads), a frozen-basket Pharma R&D Automation Index, oversight metrics and governance triggers for 2026.

Compare Veeva CDB/DQS, Medidata Clinical Data Studio, elluminate and CluePoints in 2026. Examine cross-source review, query write-back, pricing evidence and a synthetic proof-of-concept pack.

A 2026 guide to privacy-preserving record linkage for pharma RWE: trust boundaries, deterministic and probabilistic methods, reference-sample validation, precision, recall, and drift monitoring.

A 2026 reference for ANDA teams: distinguish Orange Book RLD and reference standard roles, preserve AB-number TE groups, reproduce a 48,865-row census and implement versioned reference-product joins.

A 2026 guide to GxP data migration validation, with an evidence matrix, reconciliation formulas, sampling limits, cutover and rollback controls, and separate source-retirement decisions.

A 2026 evidence framework for Claude in rare-disease R&D, covering variant interpretation, natural-history curation, IND drafting, DisMech validation, and expert review gates.

Standards-first guide to DICOM de-identification in clinical trials for 2026: PS3.15 Annex E profile options, a 13-row decision matrix, a synthetic test corpus spec and eight validation metrics.

Architecture guide to DICOM whole slide imaging integration in 2026: scanner to LIS identity chain, tiled WSI, DICOMweb, PACS/VNA, annotations and AI results, with capacity worksheets and RFP questions.

A 2026 reference matrix mapping FDA product-specific guidance revisions to ANDA study stages: critical to editorial categories, the 21 August batch of 55 draft PSGs, a change register schema and a TWYNEO worked example.

Practical 2026 guide to NDC code normalization: FDA 4-4-2, 5-3-2 and 5-4-1 patterns, 11-digit padding, the 12-digit rule effective March 7, 2033, RxNorm joins, openFDA ingestion and test fixtures.

Compare ValGenesis, Kneat Gx, and Veeva Validation Management in 2026 across CQV, CSV/CSA, cleaning, traceability, integrations, migration, pricing evidence, and a scripted buyer demonstration.

A 2026 guide to Claude Science private HPC deployment: compare SSH, bastions and AWS SSM, define least-privilege access, and build evidence and qualification controls for pharma research.

2026 guide to lab instrument integration architecture: separating SiLA 2 control from Allotrope data, comparing four coexistence patterns, LIMS and ELN roles, vendor APIs, OPC UA LADS, and pilot tests.

A 2026 analysis of why clinical trials stop early: a reproducible 23-record ClinicalTrials.gov census, reason codebook, phase and sponsor comparisons, recruitment risk matrix and evidence limits.

A 2026 guide to FDA IID maximum potency versus maximum daily exposure, with unit conversions, route and dosage-form matching, illustrative calculations, and a reproducible excipient screening method.

A 2026 comparison of assay data workflows in Genedata Screener, IDBS ActivityBase and Dotmatics, with QC formulas, a synthetic plate dataset, provenance checks and a practical migration rubric.

A 2026 germline comparison of DRAGEN, Sentieon DNASeq/DNAscope, and NVIDIA Parabricks, covering versioned deployment, GIAB truth sets, SNP/indel accuracy, measured runtime, costs, and change control.

A 2026 FDA companion diagnostic drug label crosswalk with seven selected relationships, specimen and biomarker requirements, PMA supplements, label-version gaps, and a machine-readable data dictionary.

Compare SuperPro Designer, Dynochem Biologics and Aspen Plus in 2026: model boundaries, batch scheduling, scale-up, licensing questions and an editable antibody-process throughput and cost worksheet.

A 2026 acceptance protocol for Claude Science biotech R&D pilots: independent reference tasks, reproducibility tests, citation audits, review burden, data boundaries, and expand-or-stop decisions.

A 2026 FDA REMS programs list with 68 current programs, verified participant duties, ETASU classifications, and a practical EHR integration and audit-evidence matrix.

A 2026 guide to FDA Purple Book database fields, CSV downloads, reference-product joins and product-level interchangeability, with a verified crosswalk and reproducible snapshot counts.

A 2026 guide to Claude Team for academic labs: eligibility, free Standard and $15 Premium seats, twelve-month budgets, renewal exposure, university approvals, and a measurable research pilot.